Between January and June 2018, Russia imported 46.3 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 30.3% higher than that of the same period of 2017. In physical terms, the dynamics are -4.5%, which is true for the import of both pharmacopoeial and technical APIs. Since January 208, Russia has imported 5.4 tons of APIs.

The worst dynamics in physical terms belongs to amoxicillin (-39%), paracetamol (-35%), piracetam (-33%), and metronidazole (-33%.) However, despite the big import decrease, these APIs are among the leaders in the import volume.

There have also been changes in the import line. Between January and June 2018, Russia imported APIs of 496 INN names, while in 2017 it was 472. We can see 27 new pharmacopoeial APIs, with insulinum glarginum (imported by Sanofi) and insulinum detemirum (by Novo-Nordisk) leading in the import volume in monetary terms. The number of technical API names has decreased by 6, in particular, Russia stopped importing clozapine (Organica) and vancomycinum (Sintez and Miracle Pharma.) The number of importers of technical APIs has risen from 72 to 80, while that of pharmacopoeial APIs has risen from 425 to 433. Among the newcomers, Arene Lifesciences (India) is the leader, while importing only 4 APIs (for Pharmasyntez): pharmacopoeial abacavirum and technical atazanavirum, ritonavirum, and lopinavirum.

Dynamics of pharmacopoeial and technical API import to Russia (2015 – 2017, January – June 2018), bln RUB